Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 2019

20190513-Resultats-Q1-2019-EN-

Published 13 May 2019
Categorized as 2019, Press release

Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer

20190513 PR IND TG4050 EN

Published 13 May 2019
Categorized as 2019, Myvac, Press release, TG4050

Transgene Announces Upcoming Investor Meetings

20190509 PR financial meetings Q2 19

Published 9 May 2019
Categorized as 2019, Press release

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019

20190509MISE A DISPO AG – US

Published 9 May 2019
Categorized as 2019, Press release

Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies

20190502 – TG-AZ agreement – ENG

Published 2 May 2019
Categorized as 2019, Invir.IO, Press release

Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors

20190326 PR BioInvent extension CDR US

Published 26 March 2019
Categorized as 2019, Invir.IO, Press release

Transgene: A positive 2018, moving ahead with a strong portfolio

20180320 FY RESULTS EN

Published 20 March 2019
Categorized as 2019, Press release

Transgene secures a €20 Million Revolving Credit Facility with Natixis

20190318 PR Natixis loan EN

Published 18 March 2019
Categorized as 2019, Press release

NEOVIVA project supporting the development of myvac® awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme

20190313 – Neoviva – EN

Published 13 March 2019
Categorized as 2019, Press release

Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC

20190305-PR-NEC-Agreement-US-1

Published 5 March 2019
Categorized as 2019, Myvac, Press release, TG4050

Posts pagination

Newer posts Page 1 … Page 22 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu